NYSE:JNJPharmaceuticals
Johnson And Johnson’s Darzalex Home Use Approval Reshapes Myeloma Care Narrative
Johnson & Johnson (NYSE:JNJ) has secured European approval for self or caregiver administration of Darzalex in multiple myeloma.
The decision covers all ten approved indications for Darzalex and makes it the first oncology injectable in Europe to receive this type of authorization.
The new label allows eligible patients to receive treatment at home instead of exclusively in hospital or clinic settings.
For Johnson & Johnson, which has a large pharmaceutical segment focused on oncology and...